Journal of Cancer Research and Therapeutics Close
 

Figure 1: Positron emission tomography-computed tomography imaging during the treatment. (a) Positron emission tomography-computed tomography imaging showed intensely (18F) fluorodeoxyglucose-avid in left cervical lymph nodes and retroperitoneal lymph nodes after first-line treatment with herceptin and dicycloplatin for 7 cycles. (b) Positron emission tomography-computed tomography imaging showed decreased (18F) fluorodeoxyglucose-avid in the left retroperitoneal lymph nodes after treatment with lapatinib for 3 months. (c) After treatment with lapatinib for 9 months, positron emission tomography-computed tomography imaging showed decreased (18F) fluorodeoxyglucose-avid in cervical lymph nodes and left supraclavicular lymph nodes. The foci of cervical lymph nodes and left supraclavicular lymph nodes reduced and left retroperitoneal lymph nodes almost disappeared. (d) After treatment with lapatinib for 13 months, positron emission tomography-computed tomography imaging showed increased (18F) fluorodeoxyglucose-avid in some of the cervical lymph nodes and retroperitoneal lymph nodes. Some of the cervical lymph nodes enlarged. (e) After treatment with ipilimumab for four times, positron emission tomography-computed tomography imaging showed decreased (18F) fluorodeoxyglucose-avid in some of the cervical lymph nodes, left supraclavicular lymph nodes, and retroperitoneal lymph nodes. Some of the cervical lymph nodes, left supraclavicular lymph nodes, and retroperitoneal lymph nodes reduced. (f) After treatment with ipilimumab for 14 months (treatment with ipilimumab for six times), positron emission tomography-computed tomography imaging showed decreased (18F) fluorodeoxyglucose-avid in some of the cervical lymph nodes, left supraclavicular lymph nodes, and retro-peritoneal lymph nodes. Some of the cervical lymph nodes, left supraclavicular lymph nodes, and retroperitoneal lymph nodes reduced

Figure 1: Positron emission tomography-computed tomography imaging during the treatment. (a) Positron emission tomography-computed tomography imaging showed intensely (18F) fluorodeoxyglucose-avid in left cervical lymph nodes and retroperitoneal lymph nodes after first-line treatment with herceptin and dicycloplatin for 7 cycles. (b) Positron emission tomography-computed tomography imaging showed decreased (18F) fluorodeoxyglucose-avid in the left retroperitoneal lymph nodes after treatment with lapatinib for 3 months. (c) After treatment with lapatinib for 9 months, positron emission tomography-computed tomography imaging showed decreased (18F) fluorodeoxyglucose-avid in cervical lymph nodes and left supraclavicular lymph nodes. The foci of cervical lymph nodes and left supraclavicular lymph nodes reduced and left retroperitoneal lymph nodes almost disappeared. (d) After treatment with lapatinib for 13 months, positron emission tomography-computed tomography imaging showed increased (18F) fluorodeoxyglucose-avid in some of the cervical lymph nodes and retroperitoneal lymph nodes. Some of the cervical lymph nodes enlarged. (e) After treatment with ipilimumab for four times, positron emission tomography-computed tomography imaging showed decreased (18F) fluorodeoxyglucose-avid in some of the cervical lymph nodes, left supraclavicular lymph nodes, and retroperitoneal lymph nodes. Some of the cervical lymph nodes, left supraclavicular lymph nodes, and retroperitoneal lymph nodes reduced. (f) After treatment with ipilimumab for 14 months (treatment with ipilimumab for six times), positron emission tomography-computed tomography imaging showed decreased (18F) fluorodeoxyglucose-avid in some of the cervical lymph nodes, left supraclavicular lymph nodes, and retro-peritoneal lymph nodes. Some of the cervical lymph nodes, left supraclavicular lymph nodes, and retroperitoneal lymph nodes reduced